HK Stock Market Move | ASCLETIS-B (01672) rose nearly 5% in early trading as the company launched a Phase I obesity study in the U.S. for ASC36 oral tablets.

ASCLETIS-B (01672) rose nearly 5% in early trading. As of the time of writing, it has increased by 4.97% to HKD 10.56, with a trading volume of HKD 855,400. In terms of news, Galmed Pharmaceuticals announced that it has initiated the U.S. Phase I study of ASC36 oral tablets (an oral amylopectin receptor agonist peptide) for the treatment of obesity, following the recent approval of its new drug clinical trial (IND) by the U.S. Food and Drug Administration (FDA). Dr. Wu Jinzi, founder, chairman of the board, and CEO of Galmed, stated that in 2026, we will have launched four Phase I studies in our peptide pipeline, with ASC36 oral tablets being the fourth and the latest. This marks an important milestone in Galmed's peptide pipeline and further validates our proprietary POTENT oral peptide delivery technology.